Results from vaccine trials against COVID-19 developed with Pfizer for six-month-old babies is expected by BioNTech by September, according to the German magazine Spiegel, citing the company’s CEO.
“The first results may be available in July for children aged five to 12, in September for younger children”, Ugur Sahin told Spiegel, adding that it takes four to six weeks for the data to be evaluated.
“If all goes well, once the data is evaluated, we will be able to apply for vaccine approval for all children in the respective age group in different countries,” he said.
A BioNTech spokesman confirmed the timetable for the test results in younger children.
The BioNTEch and Pfizer asked U.S. regulators this month to approve their immunization license for adolescents aged 12 to 15 years.
Sahin told Spiegel that the company was “in the final stages of submission” to European regulators. [του εμβολίου της] for children aged 12 and over. The evaluation is expected to last four to six weeks, which means that the BioNTech vaccine is likely to be approved for use in the EU by this age group as early as June. The company spokeswoman, however, declined to comment on the timing of the application.
A test released in late March showed that the two companies’ vaccine against COVID-19 is safe, effective and produces a strong immune response in adolescents, as reported by Reuters and Agence France-Presse and relayed by the Athens News Agency.
The Pfizer / BioNTech vaccine, given in two doses, is already licensed for those 16 years of age and older.
Young people are less likely to become seriously ill with COVID-19 and more likely to become infected without symptoms, passing on COVID-19 to others.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
